Regenxbio Product RGX-121 for the Treatment of MPS II Achieves Primary Endpoint

Regenxbio Product RGX-121 Achieves Primary Endpoint

From Regenxbio (RGNX) we learned that results from the Phase I/II/III CAMPSIITE® trial of the firm’s product RGX-121 for the treatment of 5 years old patients diagnosed with Mucopolysaccharidosis Type II (MPS II), also known as Hunter syndrome, demonstrated that the pivotal phase of the trial met its primary . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.